158 related articles for article (PubMed ID: 29891845)
21. Structural basis of cell surface receptor recognition by botulinum neurotoxin B.
Chai Q; Arndt JW; Dong M; Tepp WH; Johnson EA; Chapman ER; Stevens RC
Nature; 2006 Dec; 444(7122):1096-100. PubMed ID: 17167418
[TBL] [Abstract][Full Text] [Related]
22. A substrate sensor chip to assay the enzymatic activity of Botulinum neurotoxin A.
Lévêque C; Ferracci G; Maulet Y; Grand-Masson C; Blanchard MP; Seagar M; El Far O
Biosens Bioelectron; 2013 Nov; 49():276-81. PubMed ID: 23787358
[TBL] [Abstract][Full Text] [Related]
23. Preliminary crystallographic studies of a protease resistant botulinum neurotoxin associated protein Hn-33.
Hadfield AT; Petsko G; Lindo P; Singh BR
Acta Crystallogr D Biol Crystallogr; 1999 Jun; 55(Pt 6):1237-9. PubMed ID: 10329796
[TBL] [Abstract][Full Text] [Related]
24. Botulinum neurotoxin A and neurotoxin E cleavage products of synaptosome-associated protein of 25 kd exhibit distinct actions on pancreatic islet beta-cell Kv2.1 channel gating.
He Y; Elias CL; Huang YC; Gao X; Leung YM; Kang Y; Xie H; Chaddock JA; Tsushima RG; Gaisano HY
Pancreas; 2008 Jan; 36(1):10-7. PubMed ID: 18192874
[TBL] [Abstract][Full Text] [Related]
25. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
[TBL] [Abstract][Full Text] [Related]
26. Substrate recognition strategy for botulinum neurotoxin serotype A.
Breidenbach MA; Brunger AT
Nature; 2004 Dec; 432(7019):925-9. PubMed ID: 15592454
[TBL] [Abstract][Full Text] [Related]
27. Small molecule non-peptide inhibitors of botulinum neurotoxin serotype E: Structure-activity relationship and a pharmacophore model.
Kumar G; Agarwal R; Swaminathan S
Bioorg Med Chem; 2016 Sep; 24(18):3978-3985. PubMed ID: 27353886
[TBL] [Abstract][Full Text] [Related]
28. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.
Wang J; Zurawski TH; Meng J; Lawrence GW; Aoki KR; Wheeler L; Dolly JO
FASEB J; 2012 Dec; 26(12):5035-48. PubMed ID: 22942075
[TBL] [Abstract][Full Text] [Related]
29. The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems.
Kumar R; Dhaliwal HP; Kukreja RV; Singh BR
Semin Neurol; 2016 Feb; 36(1):10-9. PubMed ID: 26866491
[TBL] [Abstract][Full Text] [Related]
30. TCEP treatment reduces proteolytic activity of BoNT/B in human neuronal SHSY-5Y cells.
Shi X; Garcia GE; Neill RJ; Gordon RK
J Cell Biochem; 2009 Aug; 107(5):1021-30. PubMed ID: 19492407
[TBL] [Abstract][Full Text] [Related]
31. Persistence of botulinum neurotoxin action in cultured spinal cord cells.
Keller JE; Neale EA; Oyler G; Adler M
FEBS Lett; 1999 Jul; 456(1):137-42. PubMed ID: 10452545
[TBL] [Abstract][Full Text] [Related]
32. Botulinum Endopeptidase: SAXS Experiments and MD Simulations Reveal Extended Solution Structures That Account for Its Biochemical Properties.
Kumar R; Maksudov F; Kononova O; Marx KA; Barsegov V; Singh BR
J Phys Chem B; 2020 Jul; 124(28):5801-5812. PubMed ID: 32543194
[TBL] [Abstract][Full Text] [Related]
33. Role of metals in the biological activity of Clostridium botulinum neurotoxins.
Eswaramoorthy S; Kumaran D; Keller J; Swaminathan S
Biochemistry; 2004 Mar; 43(8):2209-16. PubMed ID: 14979717
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol.
Cai S; Sarkar HK; Singh BR
Biochemistry; 1999 May; 38(21):6903-10. PubMed ID: 10346912
[TBL] [Abstract][Full Text] [Related]
35. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
Adler M; Keller JE; Sheridan RE; Deshpande SS
Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
[TBL] [Abstract][Full Text] [Related]
36. Botulinum neurotoxin type A: Actions beyond SNAP-25?
Matak I; Lacković Z
Toxicology; 2015 Sep; 335():79-84. PubMed ID: 26169827
[TBL] [Abstract][Full Text] [Related]
37. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
38. Development of a fusion protein SNVP as substrate for assaying multi-serotype botulinum neurotoxins.
Luo S; Li T; Wang Q; Tian R; Liu H; Fang H; Chen F; Wang H
Anal Biochem; 2014 Oct; 463():75-81. PubMed ID: 23851341
[TBL] [Abstract][Full Text] [Related]
39. Role of neurotoxin associated proteins in the low pH induced structural changes in the botulinum neurotoxin complex.
Chellappan G; Kumar R; Cai S; Singh BR
Protein J; 2014 Dec; 33(6):557-64. PubMed ID: 25408485
[TBL] [Abstract][Full Text] [Related]
40. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.
Dolly JO; Wang J; Zurawski TH; Meng J
FEBS J; 2011 Dec; 278(23):4454-66. PubMed ID: 21645262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
